News

Public · Published

OPK: Revenue grew 16% as the Labcorp sale reshapes the business around biotech and global products

Third-quarter revenue from continuing operations grew 16% year over year to $65.4 million. A planned sale of assets to Labcorp would provide about $722 million in cash and complete the diagnostics exit. Full-year continuing-operations revenue guidance is $268 million to $278 million.

Published:

Updated:

What happened

Third-quarter revenue from continuing operations grew 16% year over year to $65.4 million. A planned sale of assets to Labcorp would provide about $722 million in cash and complete the diagnostics exit. Full-year continuing-operations revenue guidance is $268 million to $278 million.

Confirmed

Global impact / market context

The planned sale could provide substantial cash while removing the diagnostics business, making biotech and global products more central to the company. Revenue growth and full-year guidance give investors measures of the business it plans to keep, but do not show whether that business is profitable or can sustain growth.

Analyst inference

The reported growth applies to continuing operations, not the whole business before the planned diagnostics exit. If the Labcorp sale is completed, investors would assess a reshaped company and whether its remaining businesses can support future revenue; the supplied article does not report that the sale has closed.

Analyst inference

What to watch

  1. Watch for confirmation that the planned Labcorp asset sale closes and whether the company receives the stated approximately $722 million in cash. Analyst inference
  2. Compare later continuing-operations revenue with the $268 million to $278 million full-year guidance to assess whether the business is tracking that range. Analyst inference
  3. Look for details on how sale proceeds may be used and how leaving diagnostics changes the company’s business mix, costs, and ability to fund growth. Analyst inference

Evidence

  • Original source link unavailable